Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Merck
Dow
US Army
Farmers Insurance
Baxter
UBS
Cantor Fitzgerald
Cerilliant

Generated: December 10, 2018

DrugPatentWatch Database Preview

KEPPRA Drug Profile

« Back to Dashboard

When do Keppra patents expire, and when can generic versions of Keppra launch?

Keppra is a drug marketed by Ucb Inc and is included in four NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has twenty-nine patent family members in twenty-five countries.

The generic ingredient in KEPPRA is levetiracetam. There are thirty-five drug master file entries for this compound. Ninety-eight suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

US Patents and Regulatory Information for KEPPRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc KEPPRA levetiracetam INJECTABLE;IV (INFUSION) 021872-001 Jul 31, 2006 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ucb Inc KEPPRA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 022285-001 Sep 12, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-001 Nov 30, 1999 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc KEPPRA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 022285-002 Feb 12, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc KEPPRA levetiracetam SOLUTION;ORAL 021505-001 Jul 15, 2003 AA RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-004 Jan 6, 2006 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for KEPPRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-002 Nov 30, 1999 ➤ Sign Up ➤ Sign Up
Ucb Inc KEPPRA levetiracetam INJECTABLE;IV (INFUSION) 021872-001 Jul 31, 2006 ➤ Sign Up ➤ Sign Up
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-002 Nov 30, 1999 ➤ Sign Up ➤ Sign Up
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-003 Nov 30, 1999 ➤ Sign Up ➤ Sign Up
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-001 Nov 30, 1999 ➤ Sign Up ➤ Sign Up
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-004 Jan 6, 2006 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for KEPPRA
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablet 500 mg and 750 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Tablets 1000 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablets 1000 mg ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for KEPPRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00028 Netherlands ➤ Sign Up PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
00C/032 Belgium ➤ Sign Up PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Baxter
Cantor Fitzgerald
Mallinckrodt
Dow
Johnson and Johnson
Moodys
Argus Health
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.